- Name: Jun Ma
- Title: Academician of the Chinese Academy of Sciences, Professor and Executive Vice-president of SYSUCC
- Email: majun@sysucc.org.cn
- Phone:
Jun Ma is a professor of Radiation Oncology and deputy president of Sun Yat-sen University Cancer Center, director of the Key Laboratory of Multidisciplinary Diagnosis and Treatment of Nasopharyngeal Carcinoma, convener of the 8th Discipline Evaluation Group (Special Medicine Group) of the Academic Degrees Committee of the State Council, Member of the Department of Life Medicine of the 8th Science and Technology Committee of the Ministry of Education, chairman of the First Committee of the Nasopharyngeal Carcinoma of the Chinese Society of Clinical Oncology (CSCO), chairman of the Fifth Committee of the Nasopharyngeal Carcinoma of the Chinese Anti-Cancer Association (CACA), and co-chairman of the Chinese Society of Clinical Oncology and American Society of Clinical Oncology (CSCO-ASCO) Nasopharyngeal Cancer Clinical Diagnosis and Treatment Guidelines Committee. He was elected as academician of the Chinese Academy of Sciences in 2023.
Prof. Ma graduated from Hu Nan Medical University, Changsha, China in 1985, and gained his M.D. from Sun Yat-sen University of Medical Sciences, Guangzhou, China in 1990. He subsequently completed a 2-year postdoctoral fellowship program in Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
He serves as a reviewer and member of the editorial boards of many peer-reviewed journals. As the first author and/or corresponding author, Prof. Ma has published over 50 papers in prestigious, international peer-reviewed journals, such asNEJM, Lancet,Nat Med, JAMA, BMJ, J Clin Oncol, Lancet Oncol, JAMA Oncol, Clin Cancer Res, Cancer, Radiology, Radiother Oncol, Int J Radiat Oncol Biol Phys, and so on.
The main research interest of Prof. Ma is prognosis prediction and comprehensive treatment of nasopharyngeal carcinoma. He has done a solid job in improving the TNM staging system and investigating novel therapeutic strategies for nasopharyngeal carcinoma. He has been the Principal or Co-Principal Investigator of several multi-center clinical trials and translational research projects, including two Key Clinical Projects from the Ministry of Health (2007-2009 & 2011-2013).
His achievements won 2 items of "Top Ten Scientific and Technological Advances in Chinese Universities" (2012, 2019), 2 items of "Top Ten Advances in Chinese Life Sciences of China Association for Science and Technology" (2020, 2021), and 2 "Major Advances in Chinese Medicine of Chinese Academy of Medical Sciences" (2020, 2022), 2 "First Prize of Chinese Medical Science and Technology Award" (2014, 2022). He has received the “Ho Leung Ho Lee – Science and Technology Progress Award” (2022), “Tan Jia-Zhen Life Science Award - Clinical Medicine Award (2023)”, “Wu Jie-Ping – Medicine and Pharmacy Innovation Award (2022)”, “Guangdong Province Outstanding Contribution Award” (2018), “Chinese Medical Science and Technology Award” (2007), “National Science and Technology Progress Award” (2009), and “Guangdong Province Dingying Science & Technology Progress Award” (2009). He was honored as “China Medical Board (CMB) Distinguished Professor”, “the Outstanding Expert of the Ministry of Health of China” and “Distinguished Professor of Guangdong Province Universities and Colleges Pearl River Scholar”.
Precise diagnosis, radiotherapy, immunotherapy, and individualized management combining multiple treatment modalities of nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic research focusing on biomarkers, prognostic molecules, and signal pathways related with the development of NPC.
For information on Professor Ma's laboratory, click here and select: Prognosis prediction and comprehensive treatment of NPC.06/2000-06/2002 Postdoctoral fellow in Radiation Oncology, Anderson Cancer Center, Houston, TX
07/1987-09/1990 Master’s degree of Oncology, Sun Yat-sen University of Medical Sciences, Guangzhou, China
07/1980-09/1985 Bachelor of Medicine, Hu Nan Medical University, Changsha, China
1. Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J（Corresponding author）. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303-313. (IF 168.9)
2. Chen YP, Chan AT, Le QT, Blanchard P, Sun Y, Ma J（Corresponding author）. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80. (IF 168.9)
3. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, and Ma J（Corresponding author）. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Eng J Med. 2019;381(12):1124-1135. (IF 158.5)
4. Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, Liang XY, Zhang Y, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N, Li GB, Kuang DM, Sun Y, Ma J（Corresponding author）. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29(6):1424-1436. (IF 82.9)
5. Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J（Corresponding author）. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328(8):728-736. (IF 120.7)
6. Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J（Corresponding author）. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. (IF 105.7)
7. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J（Corresponding author）. Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. BMJ. 2018;363:k4226. (IF 105.7)
8. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J（Corresponding author）. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39(7):840-859. (IF 45.2)
9. Ma J（First & Corresponding author）, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY, Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma, J Clin Oncol. 2001; 19(5): 1350-1357. (IF 45.2)
10. Tang LL, Huang CL, Zhang N, Jiang W, Wu YS, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L, Zhou GQ, Ma J（Corresponding author）. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479-490. (IF 54.4)
11. Tang XR, Li YQ, Liang SB, Jiang W, Liu F, Ge WX, Tang LL, Mao YP, He QM, Yang XJ, Zhang Y, Wen X, Zhang J, Wang YQ, Zhang PP, Sun Y, Yun JP, Zeng J, Li L, Liu LZ, Liu N, Ma J（Corresponding author）. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382-393. (IF 51.1)
12. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J（Corresponding author）. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11):1509-1520. (IF 51.1)
13. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J（Corresponding author）. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. (IF 51.1)
14. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J（Corresponding author）. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13(2):163-71. (IF 51.1)
15. Chen YP, Wang YQ, Lv JW, Li YQ, Chua M, Le QT, Lee N, Colevas AD, Seiwert T, Hayes D, Riaz N, Vermorken J, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N, Ma J（Corresponding author）. Identification and Validation of Novel Microenvironment-based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy. Ann Oncol. 2019;30:68-75. (IF 50.5)
16. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J（Corresponding author）. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26(1):205-11. (IF 50.5)
17. Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K, Kuang DM, Li GB, Liu N, Ma J（Corresponding author）. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020 Nov;30(11):1024-1042. (IF 44.1)
18. Zhang P, He Q, Wang Y, Zhou G, Chen Y, Tang L, Zhang Y, Hong X, Mao Y, He Q, Yang X, Liu N, Ma J（Corresponding author）. Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduct Target Ther. 2022;7(1):46. (IF 39.3)
19. Liu N, He QM, Chen JW, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Ma J（Corresponding author）. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer. 2014; 13:111. (IF 37.3)
20. Liu N, Jiang N, Guo R, Jiang W, He QM, Xu YF, Li YQ, Tang LL, Mao YP, Sun Y, Ma J（Corresponding author）. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013; 12(1):123. (IF 37.3)
21. Chen YP, Lv JW, Mao YP, Li XM, Li JY, Wang YQ, Xu C, Li YQ, He QM, Yang XJ, Lei Y, Shen JY, Tang LL, Chen L, Zhou GQ, Li WF, Du XJ, Guo R, Liu X, Zhang Y, Zeng J, Yun JP, Sun Y, Liu N, Ma J（Corresponding author）. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021;20(1):14. (IF 37.3)
22. Liu X, Zhang Y, Tang LL, Le QT, Chua ML, Wee JT, Lee NY, O’Sullivan B, Lee AW, Sun Y, Ma J（Corresponding author）. Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018; 4(8): 1073-1079. (IF 28.4)
23. Liu X, Chen YP, Li WF, Sun Y, Guo Y, Eisbruch A, Ma J（Corresponding author）. Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncol. 2017; 3(3):414-416. (IF 28.4)
24. Tang LL, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J（Corresponding author）. Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MR imaging. Radiology. 2010; 257(1):151-7. (IF 19.7)
25. Tang LL, Chen YP, Mao YP, Wang ZX, Guo R, Chen L, Tian L, Lin AH, Li L, Sun Y, Ma J（Corresponding author）. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. J Natl Compr Canc Netw. 2017; 15(7):913-919. (IF 13.4)
26. Chen YP, Wang YQ, Li WF, Chen L, Xu C, Lu TX, Lin AH, Yao JJ, Li YC, Sun Y, Mao YP, Ma J（Corresponding author）. Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. J Natl Compr Canc Netw. 2017; 15(3):336-344. (IF 13.4)
27. Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM, Chen MY, Ma J（Corresponding author）. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clin Cancer Res. 2018; 24(8): 1824-1833. (IF 11.5)
28. Ma J (first author, corresponding author), Liu L, Tang L, Zong J, Lin A, Lu T, Cui N, Cui C, Li L. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007; 13(5):1445-52. (IF 11.5)
29. Peng H, Dong D, Fang MJ, Li L, Tang LL, Chen L, Li WF, Mao YP, Fan W, Liu LZ, Tian L, Lin AH, Sun Y, Tian J, Ma J（Corresponding author）. Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. Clin Cancer Res. 2019;25(14):4271-4279. (IF 11.5)
30. Zhang J, Wen X, Liu N, Li YQ, Tang XR, Wang YQ, He QM, Yang XJ, Zhang PP, Ma J（Corresponding author）, Sun Y. Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. J Exp Clin Cancer Res. 2017; 36(1):147. (IF 12.6)
Last updated: September 2023 by International Office, Sun Yat-sen University Cancer Center